What are mannitol and trehalose doing in the lyophilisation cake, and does their presence change how much freeze-thaw abuse a vial tolerates?

I have two vials of nominally the same compound from different suppliers. One cake is a dense white puck that sits proud in the vial; the other is a thin, almost translucent wafer at the base. The dense one lists mannitol on the technical sheet. The thin one lists nothing at all beyond the peptide and "acetate".

This has made me realise I do not know what the non-peptide content of a cake is for. Questions:

• What is mannitol doing? Is it a stabiliser, or just filler so the cake is visible?
• Trehalose and sucrose get called "cryoprotectants" and "lyoprotectants" interchangeably. Are those the same job?
• Does the presence of these excipients change how the reconstituted solution behaves — specifically, does a mannitol-containing cake give me a solution that tolerates a freeze-thaw better than a neat peptide cake?
• Is a neat cake with no excipients a red flag, or a sign of a purer product?

Research use only. I am trying to read a technical sheet properly rather than glancing at the purity figure.

Mannitol is primarily a bulking agent; trehalose and sucrose are primarily stabilisers; and the two roles are close to opposites in freeze-drying physics. That distinction answers all four of your questions.

Crystalline bulking versus amorphous stabilising

The key variable is whether an excipient crystallises during freezing or stays amorphous with the peptide.

A crystalline bulking agent gives you a mechanically strong, elegant cake that dries fast and reconstitutes fast, because a crystalline matrix has an open structure and a high collapse temperature. What it does not do is protect the peptide, because a crystallised excipient has separated from the peptide phase — it is no longer sharing a matrix with the molecule it was supposed to stabilise.

An amorphous stabiliser does the opposite. It stays mixed with the peptide, and it protects by two mechanisms: water replacement, where the sugar's hydroxyls hydrogen-bond to the peptide surface in place of the water being removed, and vitrification, where the peptide is immobilised in a glassy matrix so degradation chemistry has no mobility. The cost is that amorphous cakes are structurally weaker, dry more slowly, and collapse at lower temperatures — which is why formulators often use both, a crystalline bulking agent for structure plus an amorphous sugar for protection.

Are cryoprotectant and lyoprotectant the same job?

No, and the sloppiness matters. A cryoprotectant protects during the freezing step, against cryoconcentration and the ice interface. A lyoprotectant protects during drying and subsequent dry storage, against the loss of the hydration shell. Sugars happen to do both, which is why the terms get used interchangeably, but they are not the same requirement — sorbitol is a reasonable cryoprotectant and a poor lyoprotectant, because its very low Tg' means the dried solid is plasticised and mobile at storage temperatures.

Does it help the reconstituted solution? Mostly no

This is the part of your question with the least intuitive answer. A mannitol-containing cake gives you essentially no freeze-thaw protection in solution. Two reasons:

1. Mannitol crystallises on freezing, so it is not present in the freeze-concentrated liquid phase where the damage happens. It provides bulk in the dry cake and osmolality in the reconstituted solution, and then abandons your peptide at precisely the moment protection would matter.
2. Even if it stayed amorphous, the concentration is wrong. Cryoprotection in a formulated frozen protein stock uses sugar at tens of milligrams per millilitre — often a sugar-to-protein mass ratio well above one. A cake sized to bulk out a 10 mg fill and then reconstituted into 2 mL is at a fraction of that.

A trehalose- or sucrose-containing cake is a better story, because the sugar does remain in the concentrated phase — but the concentration argument still applies. Unless the technical sheet shows a sugar mass comparable to or greater than the peptide mass, the reconstituted solution is not a cryoprotected formulation and the "do not freeze" reasoning stands unchanged.

What the excipients genuinely buy you in solution is smaller and worth knowing: mannitol contributes osmolality, which pulls a hypotonic reconstitution toward isotonic; a buffer system, if present, controls pH; and a trace polysorbate, if present, meaningfully reduces interfacial aggregation from handling and agitation. Those are real benefits for ordinary refrigerated in-use storage. They are not freeze protection.

Is a neat cake a red flag?

Neither a flag nor a virtue — it is a different product with different handling implications, and the honest reading is:

• Neat cake: thin wafer or film, sometimes barely visible, which is why people occasionally think a vial is empty. Higher peptide mass fraction, so the purity figure on the COA is the whole story. Reconstituted solution is unbuffered, hypotonic, unprotected at interfaces. Needs more careful handling and a shorter in-use window.
• Bulked and buffered cake: dense puck, obviously present, faster and more reliable reconstitution, better-behaved solution. The stated milligrams are peptide, so the excipient does not dilute your content — but you should confirm that, because a "10 mg vial" that means 10 mg total including bulking agent is a different proposition entirely, and this is a genuine source of discrepancy between label claim and content assay.

That last point is the actionable one. If a content assay from one of the independent services comes back low against label claim on a heavily bulked cake, check whether the label claim was ever peptide mass before concluding the vial was underfilled.

edited 9 Feb 2026 by wren_calloway — removed a claim I could not source

Adding the reading of the two cakes described in the question, because cake appearance is genuinely diagnostic and it is a skill worth having.

The dense white proud puck that retains the shape of the frozen fill is a well-executed lyophilisation of a bulked formulation. It tells you the fill was frozen properly, primary drying stayed below the collapse temperature, and the matrix had enough crystalline structure to hold itself up. Good sign, and it will reconstitute in seconds.

The thin translucent wafer is what a low-solids fill looks like and is usually normal for a neat peptide. Where it stops being normal:

• Translucent and glassy with a smooth, fused-looking surface rather than matte: that is not a low-solids cake, that is meltback or collapse. The fill went above its collapse temperature and the structure flowed before drying finished. Residual moisture in such a cake is typically elevated, which — via the Tg-lowering effect of water — means the whole material sits closer to its mobility threshold in storage. This is the appearance that should change how you store a vial.
• A cake that has pulled away from the glass and shrunk into a smaller mass: shrinkage after the fact, indicating a thermal excursion post-lyophilisation.
• A cake with a hard skin and a soft or hollow interior: partial meltback, often from an over-aggressive shelf ramp.

The distinction between "thin because there are few solids" and "thin because it collapsed" is surface texture. A properly dried low-solids cake is matte, porous and lifts as a discrete flake if you tilt the vial. A collapsed one is glossy, dense for its size, adheres to the glass, and often reconstitutes noticeably more slowly — which is itself the confirmatory test, since you were going to reconstitute it anyway. Note the timing to dissolve on your first vial of any lot; it is the baseline you will want later.

Small but practical: the acetate on that second technical sheet is not an excipient in the sense the others are, and it is worth knowing why it is listed.

Peptides made by solid-phase synthesis are typically purified by reverse-phase chromatography with trifluoroacetic acid, then converted to a more benign counter-ion — usually acetate — by ion exchange or repeated lyophilisation from acetic acid. So acetate content is a counter-ion, present as the salt form of basic residues, and it is reported because it is part of the mass balance.

Three consequences:

• Mass balance. Net peptide content is the label mass less counter-ion, less water, less any residual solvent and salts. This is why a content assay routinely reads below the gross weighed mass and why "peptide content" and "purity" are different quantities on a COA — purity is chromatographic peak area, content is how much peptide is actually in the vial.
• pH on reconstitution. An acetate salt reconstituted in unbuffered water gives a mildly acidic solution with some — weak — acetate buffer capacity. So the neat cake is not quite as unbuffered as it looks, though not in a way you can rely on.
• Residual TFA is the one to ask about. If a supplier reports trifluoroacetate rather than acetate, the material was never converted, and TFA content is worth knowing rather than shrugging at. It shows up on a COA under residual solvent or counter-ion, and its absence from a sheet that lists everything else is a reasonable thing to query.

None of this bears on freeze-thaw. It does bear on reading the sheet, which is what the question was actually about.